Please login to the form below

Not currently logged in
Email:
Password:

FDA advises withdrawal of Avastin approval

Advisers to the US Food and Drug Administration have recommended to withdraw approval of the metastatic breast cancer indication for Roche's Avastin as EU extends the drug's label

Advisers to the US Food and Drug Administration (FDA) have recommended to withdraw approval of the metastatic breast cancer indication for Roche's Avastin (bevacizumab).

The Oncologic Drugs Advisory Committee (ODAC) unanimously voted to halt the use of the drug in cases of breast cancer stating that the drug has not been shown to be safe and effective for the indication.

It has been suggested the withdrawal may affect Roche's annual sales by as much as $1bn by 2015. Avastin, which is also approved for the other indications of colorectal cancer, non-small cell lung cancer and kidney cancer, made CHF6.46bn (about $7.74bn) during 2010.

The decision backs a previous recommendation from the FDA in December, 2010 to withdraw Avastin's approval for breast cancer, which reviewed the results of four clinical studies of the drug in women with the disease and determined that the data indicated that the drug does not prolong overall survival in breast cancer patients or provide a sufficient benefit in slowing disease progression to outweigh the significant risk to patients.

Side-effects of the drug include stroke, wound healing complications and organ damage or failure.

The final decision is still to be made by the FDA commissioner, and Roche are scheduled to provide additional written submissions by July 28, 2011, with public comment invited until that date.

"We are very disappointed by the committee's recommendation and hope the commissioner does not decide to remove this important medicine for women with an incurable disease who already have too few treatment options," said Dr Hal Barron, chief medical officer and head, global product development at Roche. "We remain ready to collaborate with the FDA to find a solution that is in the best interest of patients who need Avastin."

In December, 2010, the UK's National Institute for Health and Clinical Excellence (NICE) recommended against the use of Avastin on the NHS for the treatment of metastatic breast cancer.

Also announced today was the EU's decision to expand the label of Avastin to allow the drug to be used in combination with Xeloda (capecitabine) as a first-line treatment.

The decision is based data from a phase III study which showed an increase in the length of time women lived without their disease getting worse when Avastin was combined with capecitabine, compared to those who received capecitabine alone.

30th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Women in science
The role of women in science and technology
Why the lack of female leaders in pharma and life sciences is a problem that still needs to be fixed...
Maria Dahl
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances
China secures a place at the forefront of innovative medicine...
Virtual Research Grants Submission and Approval Program
Impetus Digital summarizes how a client established an independent grant review committee and a virtual grant submission and approval program, without having to travel and meet in person....

Infographics